CD8A and cancer: BTLA blockade also bolsters the stimulatory effects of PD‐1 blockade on alloreactive CD8+ T cells,214 suggesting that combinatorial interference with BTLA and PD‐1 could be a useful approach for augmenting antitumor T cell responses in cancer patients.